NOV 24, 2015 12:08 PM PST

Brain Inflammation Linked to Persistant Depression Symptoms

WRITTEN BY: Kara Marker
A large number of people diagnosed with depression experience an inability to feel pleasure, and antidepressants don't seem to be helping. A new study from Emory Health Sciences has shown that inflammation in the brain is causing the disconnect, and anti-inflammatory drugs could reverse the effect.

"Anhedonia," also know as the loss in interest of previously pleasing activities like talking with friends, being outside or listening to music, is a common symptom of people with major depressive disorder (Psychology Today). Newly linked to inflammation, prior to this discovery doctors were unsure why antidepressants did not solve this problem associated with depression. 

In a study published this month in Molecular Psychiatry, scientists from Emory looked at brain images of 48 patients diagnosed with depression to investigate the potential of this "inflammatory depression." They analyzed the levels of c-reactive protein (CRP), an inflammatory marker produced by the liver in response to inflammation in the body (MedlinePlus). They collected brain images of their participants while they were not on any antidepressants or other drugs and compared the images to their CRP levels.
C-reactive protein

A clear connection was made between patients experiencing and reporting anhedonia and high levels of CRP circulating in their blood. In addition, brain images from these patients showed "low functional connectivity" between two regions of the brain related to motivation and reward. Patients with low levels of CRP did not report experiencing anhedonia and had normal connectivity between these brain regions.

"We were interested in these regions of the brain because of their known importance for response to reward," said lead author Jennifer Felger, PhD, assistant professor of psychiatry and behavioral sciences at Emory University School of Medicine and Winship Cancer Institute.

Scientists were also prompted to make this connection since decreased activity of the same two brain regions was seen in hepatitis C patients receiving "immuno-stimulatory" treatments that boosted inflammation. Scientists have begun using anti-inflammatory treatments for anhedonia patients and seen improvement. No change was seen in patients without anhedonia when given the same treatment. 

The next step, being pursued by the same group from Emory, is to test the effectiveness of L-DOPA therapy on anhedonia patients. L-DOPA therapy is currently used to treat Parkinson's disease by acting as a neurotransmitter and stimulating brain activity. 

Watch the following video to learn more about L-DOPA and how it works.

Source: Emory Woodruff Health Sciences Center
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 19, 2020
Cell & Molecular Biology
Mild COVID-19 Cases Induce an Immune Cell Response
AUG 19, 2020
Mild COVID-19 Cases Induce an Immune Cell Response
As the pandemic virus, SARS-CoV-2 continues to cause tens of thousands of new cases of COVID-19 every day in the United ...
SEP 20, 2020
Microbiology
Middle-Aged Adults Might Always be Susceptible to H3N2 Flu
SEP 20, 2020
Middle-Aged Adults Might Always be Susceptible to H3N2 Flu
People born in the late 1960s or 1970s might be perpetually susceptible to the H3N2 influenza virus, according to new re ...
OCT 06, 2020
Immunology
COVID Triggers Abnormalities in Immune Monocytes
OCT 06, 2020
COVID Triggers Abnormalities in Immune Monocytes
University of Manchester immunologists are the first to make an interesting observation about the white blood cells of p ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 09, 2020
Microbiology
Fighting COVID-19 with Help From Llamas
NOV 09, 2020
Fighting COVID-19 with Help From Llamas
Camelids, which include llamas, alpacas and camels have immune systems that generate two kinds of antibodies when confro ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
Loading Comments...